KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $192.0 million.

  • Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) rose 0.86% to $192.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.0 million, marking a year-over-year increase of 0.86%. This contributed to the annual value of $190.6 million for FY2024, which is 1.18% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Shares Outstanding (Weighted Average) stood at $192.0 million for Q3 2025, which was up 0.12% from $191.8 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) ranged from a high of $192.0 million in Q3 2025 and a low of $181.8 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $189.5 million, with a median of $189.9 million in 2024.
  • Data for Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) shows a peak YoY rose of 1.46% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) stood at $183.6 million in 2021, then increased by 1.23% to $185.8 million in 2022, then climbed by 1.36% to $188.4 million in 2023, then increased by 1.18% to $190.6 million in 2024, then climbed by 0.86% to $192.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $192.0 million for Q3 2025, versus $191.8 million for Q2 2025 and $190.8 million for Q1 2025.